Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort

Icona Foundation and HepaIcona Study Group, Antonio Cristaudo, Alessandra Latini

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Article numbere0177402
JournalPLoS One
Volume12
Issue number5
DOIs
Publication statusPublished - May 17 2017

Keywords

  • antivirus agent
  • ritonavir
  • adult
  • Article
  • CD4 lymphocyte count
  • cohort analysis
  • controlled study
  • drug efficacy
  • drug response
  • drug treatment failure
  • female
  • follow up
  • health care access
  • health care availability
  • hepatitis C
  • Hepatitis C virus genotype 3
  • human
  • Human immunodeficiency virus infection
  • Italy
  • major clinical study
  • male
  • mixed infection
  • outcome assessment
  • prediction
  • reimbursement
  • sustained virological response
  • comorbidity
  • disease management
  • genetics
  • genotype
  • health care delivery
  • Hepacivirus
  • highly active antiretroviral therapy
  • HIV Infections
  • Kaplan Meier method
  • middle aged
  • proportional hazards model
  • risk factor
  • transmission
  • treatment failure
  • treatment outcome
  • virus load
  • Adult
  • Antiretroviral Therapy, Highly Active
  • Antiviral Agents
  • CD4 Lymphocyte Count
  • Coinfection
  • Comorbidity
  • Disease Management
  • Female
  • Genotype
  • Health Services Accessibility
  • Hepatitis C
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Risk Factors
  • Treatment Failure
  • Treatment Outcome
  • Viral Load

Cite this